cornellleukemia.com
Phase 3 Trial Shows CPX-351 (Vyxeos) Boosts Overall Survival in AML
Frontline treatment with CPX-351 (Vyxeos) significantly boosted overall survival (OS) for older patients with high-risk, secondary acute myeloid leukemia (AML) when compared with the current standa…